Novo Nordisk Q3 sales beat forecasts in new CEO's maiden quarter

Novo Nordisk (NOVOb.CO) significantly lowered its full-year operating profit growth forecast to 4-7% from a prior 10-16%, and its sales growth outlook to 8-11% from 8-14%, attributing the revision to reduced growth expectations for its GLP-1 treatments amid intensifying competition from rivals like Eli Lilly. This guidance cut, an early test for new CEO Mike Doustdar, follows third-quarter sales of DKK 75.0 billion ($11.71 billion) that missed analyst consensus, indicating a notable deceleration from the rapid growth that previously propelled the Wegovy-maker to become Europe's most valuable company.

Analysis

Novo Nordisk (NVO) has significantly lowered its full-year operating profit growth forecast to 4%-7% in local currencies, down from an earlier 10%-16%, and its sales growth outlook to 8%-11% from 8%-14%. This substantial revision, attributed to "lower growth expectations for our GLP-1 treatments," marks an early challenge for new CEO Mike Doustdar, who took the helm in August. The company also reported third-quarter sales of DKK 75.0 billion ($11.71 billion), missing analyst consensus of DKK 76.2 billion.

The guidance cut and Q3 sales miss underscore intensifying competition in the obesity drug market, particularly from rivals like Eli Lilly (LLY) and emerging copycat treatments. While sales grew 11% in local currencies, this represents a sharp deceleration from previous periods, impacting the rapid growth that previously propelled Novo Nordisk to become Europe's most valuable firm. The company's ongoing restructuring drive aims to regain lost ground in this dynamic market.

The strongly negative sentiment (-0.75) and pessimistic tone surrounding this announcement suggest a significant re-evaluation of NVO's near-term growth trajectory. This development indicates fundamental pressures on its blockbuster Wegovy franchise, necessitating a strategic shift under new management, and could lead to sustained pressure on NVO's share price.

Key Decisions for Investors

• Investors should re-evaluate Novo Nordisk's long-term growth trajectory given the significant downward revision in full-year guidance and intensifying competition in the GLP-1 market.
• Closely monitor the competitive dynamics, particularly the market share gains by Eli Lilly and the impact of potential copycat treatments on Novo Nordisk's key franchises.
• Assess the effectiveness of the new CEO's restructuring initiatives and future strategic announcements for signs of successful adaptation to the evolving market landscape.